Description
Vepdegestrant is an investigational medication currently being studied in clinical trials for certain types of advanced or metastatic solid tumors, including colorectal cancer. It is being evaluated in combination with another investigational drug called PF-07248144. The trials are designed to determine the appropriate dose and assess the safety and effectiveness of this combination. Vepdegestrant is being studied in patients whose tumors have specific characteristics, such as HER2 mutations or lack of HER2 expression. It is important to note that vepdegestrant is not yet approved for use in colorectal cancer and is only available as part of a clinical trial.
Mechanism of Action
Vepdegestrant is being investigated as a potential treatment for cancers that rely on certain hormonal pathways for growth. It is designed to block the action of these hormones, potentially slowing or stopping the growth of cancer cells. The specific molecular target and detailed mechanism of action are being further characterized in ongoing clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.